Centre
for Lymphoid Cancer maintains provincial, national and international partnerships with multi-disciplinary scientific researchers and clinicians to:
The purpose of this newsletter is to provide a brief summary of the projects underway throughout our Centre
for Lymphoid Cancer program, the people that work on them, and useful information on upcoming events.
The Centre
for Lymphoid Cancer is a multi-disciplinary research program focused on the development of new treatments and diagnostics for lymphoid cancers.
Adaptive Biotechnologies» first test,
for lymphoid cancers, also determines whether a particular treatment is effective.
A multi-disciplinary research program focusing on new treatments and diagnostics
for lymphoid cancers
Not exact matches
The assay revealed
cancer subtype - specific mutational profiles that were highly similar to published mutational profiles
for all three types of
lymphoid cancer.
A new study published in The Journal of Molecular Diagnostics has established that hybrid - capture sequencing is the method of choice
for sequencing «actionable» gene mutations across the most common forms of
lymphoid cancer.
Unlike whole - genome sequencing, this assay targets a select set of genes or regions with known associations with
lymphoid cancer, allowing
for more rapid detection of a variety of mutations.
«Harnessing the power of genomic sequencing augments diagnosis and treatment of
lymphoid cancer: New assay may allow screening
for «actionable» gene mutations in routinely acquired archival biopsies, reports The Journal of Molecular Diagnostics.»
Facilitate cross-disciplinary research programs focused on understanding the biological mechanisms of
lymphoid cancers for the development of novel therapeutic treatments
for these
cancers.
Accelerate the development of novel diagnostics and therapeutics
for the treatment of
lymphoid cancers by fostering a cutting - edge multi-disciplinary research environment with a focus on clinical applications.
Lymphoid neoplasms are
cancers of the immune system, which afflict both adults and children, and account
for 6 - 10 % of all neoplastic diseases.
Steroid drugs such as prednisolone may palliate blood,
lymphoid and mast cell
cancers for a few months.
Staff Scientist
Lymphoid Malignancies Branch Center
for Cancer Research National
Cancer Institute